HROW News and Press, Harrow Health Inc. From 10/06/25

Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today ...

2025-09-29 09:08:42 ET Thomas Flaten from Lake Street issued a price target of $70.00 for HROW on 2025-09-29 12:36:53. The adjusted price target was set to $70.00. At the time of the announcement, HROW was trading at $47.1. The overall price target consensus is at $68.00...

2025-09-27 00:27:40 ET Harrow, Inc. (HROW) Analyst/Investor Day September 26, 2025 11:30 AM EDT Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO &...

2025-09-26 07:10:12 ET More on Harrow Health Harrow: Buy A Blend Of Value And Growth Harrow: A Classical GARP Stock Harrow Baby Bonds Yield Review Harrow launches $250M debt offering Harrow announces leadership changes, Andrew Boll to serve as Preside...

NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc. , a clinical-stage pharmaceuti...

HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalm...

NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. E...

2025-09-12 10:57:55 ET Introduction & Investment Thesis I am bullish on Harrow, Inc. ( HROW ) driven by the VEVYE Access for All program . This program has introduced cyclosporine ophthalmic solution for a dry eye condition by making it accessible and affordable for ...

2025-09-09 13:11:01 ET Investment Thesis I recently wrote about ETON Pharmaceuticals ( ETON ), a small company focused on acquiring drugs for ultra-rare diseases, with limited peak potential sales, which makes them less interesting for small biotech companies that own them. ...

NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $250.0 million aggregate principal amoun...